Radient Pharmaceutical Corporation’s CEO & Chairman Mr. Douglas MacLellan Featured on “The Money Channel’s American Scene Radio”
TUSTIN, CA–(Marketwire – Dec 2, 2009) – Radient
Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC), voiced currently its
Chairman and CEO Mr. Douglas MacLellan will be featured on “The Money
Channel’s American Scene Radio” with host Steve Crowley to plead Radient
Pharmaceutical’s 2010 expansion devise and the Company’s worldwide
commercialization devise for the Onko-Sure™ In Vitro (IVD) cancer exam and
Elleuxe™ high-end skin caring product line.
According to Steve Crowley of “The Money Channel’s American Scene Radio,”
“I have followed this Company’s swell closely for 5 years and see
Radient Pharmaceuticals as a clever expansion and worth play. We ask our
listeners and viewers to finish their due industry on the Company right
now since government has forecasted profitability early in 2010 and we
believe the batch is intensely undervalued formed on the potential
revenues, really tall margins, and portfolio of egghead properties.”
Douglas MacLellan, Chairman and CEO comments, “We hold we have
established a low risk trail to profitability in mercantile year 2010 and are
very assured in Radient Pharmaceutical’s destiny prospects — specifically
with the launch and commercialization of the Onko-Sure IVD cancer exam and
Elleuxe skin caring line, and the monetization of the China-based subsidiary
Jade Pharmaceuticals, Inc. We hold the Company offers a compelling
investment event and we inspire impending investors to rivet in
the business.”
Radient Pharmaceuticals is focused on the research, development,
manufacturing, sales and selling of in vitro diagnostics and high-end
skin caring products, together with the Onko-Sure IVD cancer exam and Elleuxe
skin caring product line. The Company has cumulative regulatory capitulation in the
US and multiform alternative ubiquitous markets for Onko-Sure and began
commercializing the product in the second entertain of mercantile year 2009.
Radient Pharmaceutical’s idea is to settle Onko-Sure as the premiere
test for ubiquitous cancer screening and monitoring in vital markets
within the subsequent 5 years and is raised $17.2 million in product gross
revenues in 2010, $50.7 million in year 2012, and $107.9 million by 2014.
In 2010 the Company will additionally strictly launch the Elleuxe skin care
product line.
The Money Channel brings Radient Pharmaceuticals every day bearing to the
investing public. Programming includes weekday Investor Showcase Radio
segments, together with interviews on the American Scene Radio module from
this week by May 1, 2010. Radient Pharmaceuticals will additionally present
at the World Money Show in early Feb 2010 (Orlando, FL) in the Money
Channel’s Broadcast Booth in sequence to encounter and hail intensity new
investors and income managers. The Money Channel will furnish a televised
feature shred there, to be aired on the “WallStreetCast” module which
airs weekends on the Fox Business Network (FBN) nationwide.
Doug MacLellan’s talk is scheduled for Thursday, Dec 3, 2009 at
9:00 AM Pacific Standard Time and will be accessible as an audio download
through The Money Channel website located at
http://www.americansceneradio.com/. For one more report on Radient
Pharmaceuticals and the portfolio of products, revisit the Company’s
corporate website at
www.Radient-Pharma.com. For Investor Relations information, contact
Kristine Szarkowitz at kszarkowitz@Radient-Pharma.com or 1.206.310.5323.
About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is
an integrated curative association clinging to the research, development,
manufacturing, and selling of diagnostic, and reward skin caring products.
Forward-Looking Statements:
Safe Harbor Statement underneath the Private Securities Litigation Reform Act of
1995: The statements contained in this request embody sure predictions
and projections which might be deliberate forward-looking statements under
securities law. These statements engage a series of critical risks and
uncertainties which could means tangible formula to talk about materially
including, but not singular to, the opening of corner try partners,
as good as alternative economic, rival and technological factors involving
the Company’s operations, markets, services, products, and prices. With
respect to Radient Pharmaceuticals Corporation, solely for the historical
information contained herein, the counts discussed in this request are
forward-looking statements involving risks and uncertainties which could
cause tangible formula to talk about materially from those in such
forward-looking statements.
